{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Objectives and Endpoints:', 'Objectives', 'Endpoints', 'Primary', 'To evaluate the efficacy of ANB019 in', 'Proportion of subjects achieving clinical', 'subjects with active GPP as measured by the', 'response at Week 4 and Week 16. Clinical', 'Clinical Global Impression (CGI) scale', 'response is defined as \"Very much', 'according to the modified Japanese', 'improved, \"Much improved,\\' and', 'Dermatology Association (JDA) severity', '\"Minimally improved\" on CGI scale', 'index total score', 'according to modified JDA severity index', 'total score', 'To assess the safety and tolerability of', 'Assessment of adverse events (AEs)', 'ANB019 in subjects with GPP', 'Potentially significant and clinically important', 'AEs, adverse event of special interest (AESI),', 'serious adverse events (SAEs), and AEs', 'leading to withdrawal', 'Physical examinations', 'Vital signs', '12-lead electrocardiogram (ECG)', 'Clinical safety laboratory tests (hematology,', 'biochemistry, and urinalysis)', 'Secondary', 'To evaluate the effect of ANB019 on the total', 'Change in modified JDA severity index total', 'and individual skin lesion symptoms as', 'skin lesions score (sum of erythema,', 'measured by the modified JDA severity index', 'erythema with pustules, edema) at all study', 'score', 'visits', 'Change in affected body surface area (BSA)', 'of erythema with pustules, erythema, and', 'edema as measured by modified JDA severity', 'index at all study visits', 'To evaluate the effect of ANB019 on total and', 'Change in total and individual scores in', 'individual components of systemic', 'systemic manifestations and laboratory', 'manifestations and laboratory findings as', 'findings as measured by modified JDA', 'measured by modified JDA severity index', 'severity index at all study visits', 'score', 'To evaluate the effect of ANB019 on GPP', 'Proportion of subjects achieving a GPPPGA', 'using the Generalized Pustular Psoriasis', 'score of 0 or 1 at all study visits', \"Physician's Global Assessment (GPPPGA)\", 'Change from Baseline in GPPPGA scores at', 'all study visits', 'To determine any treatment effect of ANB019', \"Change in PASI score to evaluate a subject's\", 'in plaque psoriasis (if present) as measured by', 'overall plaque psoriasis disease state, if', 'Psoriasis Area Severity Index (PASI)', 'present, at all study visits', 'To assess the effect of ANB019 on the', 'Change in Dermatology Life Quality Index', \"subject's quality of life\", '(DLQI) total score at all study visits', '29 October 2019', '9']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'To determine the pharmacokinetics (PK) of', 'Serum concentration following ANB019', 'ANB019 in GPP subjects', 'administration.', 'Following first dose administration of ANB019', 'these parameters will be determined:', 'Maximum observed concentration (Cmax),', 'time to maximum observed concentration', '(Tmax), area under the concentration-time', 'curve (AUC) and other parameters as', 'appropriate', 'To test for immunogenicity to ANB019', 'Presence of anti-drug antibodies (ADA)', 'Exploratory', 'To explore the effects of ANB019 on skin', 'Skin biopsies biomarkers (including but not', 'biopsy biomarkers', 'limited to IL-17, IL-23, IL-8, dendritic cells,', 'epidermal thickness, and leukocytes', 'infiltration)', 'To assess the effect of ANB019 on', 'Changes in serum cytokines as compared to', 'inflammatory parameters such as serum', 'baseline at Weeks 1, 4, 8, 12, 16, and 24', 'cytokines including but not limited to IL-8', 'Provide photographic documentation of', 'Photographic documentation of lesions', 'lesions', 'To explore GPP-associated mutations and', 'Optional genetic testing (deoxyribonucleic', 'additional pharmacogenomic analysis', 'acid [DNA] and messenger ribonucleic acid', '[mRNA])', 'Overall Design:', 'This is an open-label, single arm, multiple dose study aiming to assess the clinical efficacy, safety and', 'tolerability, and PK of multiple doses of ANB019 in subjects with GPP.', 'The screening period will be up to 42 days (6 weeks) prior to administration of study drug on Day 1.', 'On Day 1, subjects who meet the entry criteria will receive a 750 mg intravenous (IV) dose of ANB019 in', 'an open-label manner followed by 3 doses of 100 mg administered subcutaneously (SC) on Days 29, 57,', 'and 85. The subjects will leave the study center after completing the 5 hours postdose assessments', 'following IV administration and the 3 hours postdose assessments after the first and second SC injections', \"and with the Investigator's approval. Subjects with any ongoing AEs or SAEs at the time of scheduled\", 'discharge from the study center should remain at the study center until the Investigator has determined', 'that these events have been resolved or deemed as not clinically significant.', 'The subjects will return to the study center for follow-up visits on Day 3 and Day 8, weekly from Day 8', 'to Day 29, and then every other week up to Day 85, and monthly for 12 weeks to monitor changes in', 'disease activity, safety, and tolerability. In addition, the subjects will be contacted via phone by study', 'staff to assess for safety (eg, AEs and changes in concomitant medications) on Days 36, 50, 64, and 78.', '29 October 2019', '10']\n\n###\n\n", "completion": "END"}